BridgeMD
New treatment option for Leukemia, Lymphoblastic, Acute, Pediatric
Official title Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
ClinicalTrials.gov ID: NCT06649253
What this study is testing
- What it's testing
- B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 0 to 17
You may be able to join if
- Under 18 years
- With established diagnosis of B-ALL
- Initial diagnosis made in the investigating centre
- Having received oral and written information about the protocol, or oral only if the patient is unable to read.
- Having signed a consent form if the patient is capable of giving informed written consent.
You likely can't join if
- Isolated extramedullary involvement at inclusion
- Patient of childbearing age without effective contraception.
- Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
See the full eligibility criteria
- Under 18 years
- With established diagnosis of B-ALL
- Initial diagnosis made in the investigating centre
- Having received oral and written information about the protocol, or oral only if the patient is unable to read.
- Having signed a consent form if the patient is capable of giving informed written consent.
- Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent.
- Beneficiary of a social security scheme
- Isolated extramedullary involvement at inclusion
- Patient of childbearing age without effective contraception.
- Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
The study team makes the final eligibility decision.
Where it's taking place
- Angers, France
- Brest, France
- Rennes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Angers, France; Brest, France; Rennes, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.